Bioniche Life Sciences Inc.

Details. David J. Kaczorowski, Amin Afrazi, Melanie J. Roop Gill, Rebecca D. Edmonds, Yujian Liu, Jie Fan, and Timothy R. Billiar The pattern recognition receptor ligands lipopolysaccharide and polyinosinic – polycytidylic acid stimulate factor B synthesis by macrophages by distinct but overlapping mechanisms Leukoc J Biol 2013 88:. 609th DOI: 10.1189/jlb.

The information from this research will ultimately help to develop new drugs and treatments that health care providers in order to have the uncontrolled immune responses that have devastating consequences for the people can prevent. – Helps our study are to understand exactly how the immune system is activated when it comes to infection from bacteria or viruses, said Melanie J., an author of the research report of the Department of Surgery at the University of Pittsburgh, Pennsylvania.Bioniche Life Sciences Inc. , a research based, technology driven Canadian biopharmaceutical company, announced achieving a U.S. $ 4, milestone payments development partner for, Endo Pharmaceuticals Inc. This milestone is said fourth on Bioniche connected to the parties to the, the implementing their agreement in July 2009.

$ 9,000 loan from the sale.

In North America, bladder cancer be the fourth leading cancer in men and to the fifth place between the two men and female. The United States, as 70,000 patients bladder cancer with bladder cancer annually and 500,000 live patients are affected. The cancer diseases the a lot above patients diagnosed remain unsolved, sometimes leading to radical cystectomy or death. Roughly 70 % of patients with bladder cancer who which Do not – muscle-invasive from bladder cancer and on regulatory approvals, the licensing agreement of several treatments by UrocidinTM.

Except for historical information this press release may contain forward-looking statements, which reflect the Company ‘s current expectation regarding future events.